|
Acute Promyelocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here we show that, in acute promyelocytic leukaemia (APL), ILC2s are increased and hyper-activated through the interaction of CRTH2 and NKp30 with elevated tumour-derived PGD2 and B7H6, respectively.
|
28928446 |
2017 |
|
Adenoma of large intestine
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we studied expression of DP1 and DP2 receptors by reverse transcription-polymerase chain reaction analysis of receptor mRNA levels in five human colorectal cancer cell lines (HT-29, HCA-7, HCT116, SW480 and SW48) and VACO-235 human colorectal adenoma cells.
|
15172124 |
2004 |
|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pharmacologically, rat CRTH2 stably transfected in mouse preB lymphoma L1.2 cells behaved very similar compared with the mouse and human orthologs, showing a binding affinity for PGD2 of 11 nM, a functional calcium mobilization when exposed to agonist, and similar sensitivity to agonists and antagonists.
|
12975488 |
2003 |
|
airway disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CRTh2 rs533116 was associated with allergic asthma in White people (2.67 [1.09-6.55], P < 0.05), and expression of CRTh2 was higher in subjects with allergic airways disease compared to controls (P < 0.05).
|
22947041 |
2012 |
|
Allergic asthma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Fevipiprant, an oral prostaglandin DP<sub>2</sub> receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids.
|
28838980 |
2017 |
|
Allergic asthma
|
0.040 |
Biomarker
|
disease |
BEFREE |
AZD1981 is an orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) receptor antagonist progressed to phase II trials for the treatment of allergic asthma.
|
27558866 |
2017 |
|
Allergic asthma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Here, we assessed the association between CRTh2 rs533116 and allergic asthma, expression of CRTh2 and Th2 cytokine production.
|
22947041 |
2012 |
|
Allergic asthma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β<sub>2</sub>-agonists in patients with atopic asthma.
|
29765200 |
2018 |
|
Allergic rhinitis (disorder)
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results open channels for therapeutic modalities targeting CRTH2 molecules in AR.
|
28222358 |
2017 |
|
Allergic rhinitis (disorder)
|
0.030 |
Biomarker
|
disease |
BEFREE |
PGD<sub>2</sub> -CRTH2 and cysLTs-CysLT1 axes may activate tissue-resident ILC2s to produce Th2 cytokines, IL-5 and IL-13, leading to the development of allergic inflammation in AR.
|
31267527 |
2019 |
|
Allergic rhinitis (disorder)
|
0.030 |
Biomarker
|
disease |
BEFREE |
The clear discrepancy between animal studies and clinical efficacy of CRTH2 antagonism in allergic rhinitis, and lack of efficacy in a general cohort of asthmatics, highlight the issue of patient phenotyping.
|
28612233 |
2017 |
|
Allergic sensitization
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation within CRTh2 modifies the development of allergic sensitization and asthma in a population of German children.
|
19392992 |
2009 |
|
Aspirin exacerbated respiratory disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A significant difference in the genotype frequencies of CRTH2 -466T>C was detected between AERD and ATA patients (P < 0.05).
|
19796209 |
2010 |
|
Aspirin exacerbated respiratory disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Thromboxane A2 receptor +795T>C and chemoattractant receptor-homologous molecule expressed on Th2 cells -466T>C gene polymorphisms in patients with aspirin-exacerbated respiratory disease.
|
22101342 |
2012 |
|
Asthma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Family-based analysis of asthma and two common SNPs [G1544C and G1651A (rs545659)] in the 3'-untranslated region of CRTH2 showed significant evidence of linkage in the presence of disequilibrium for the 1651G allele (P = 0.003) of SNP rs545659.
|
15345705 |
2004 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, genetic association studies have shown a positive linkage of the genetic polymorphisms in DP and CRTH2, with asthma phenotypes from specific ethnic backgrounds, further highlighting the importance of PGD(2) and its receptors in the pathophysiology of asthma.
|
18946232 |
2008 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation.
|
18757520 |
2008 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on current data we propose that blocking CRTH2 might be a potential therapeutic approach to numerous conditions beyond classical allergic diseases and asthma.
|
28818625 |
2017 |
|
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data failed to support previous associations of functional polymorphisms at the 3'-UTR of the CRTH2 gene implicated in asthma.
|
17016057 |
2007 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previous suggested that PAR-2 and CRTh2 expression on specific peripheral blood cell subtypes may be biomarkers of asthma severity.
|
31168305 |
2019 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Current treatment options for severe asthma are inadequate and therapeutic antibody-mediated depletion of CRTh2-expressing cells represents a promising new therapeutic strategy.
|
27103662 |
2016 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, a number of CRTH2 antagonists are under clinical investigation, and one compound, fevipiprant, has advanced to phase 3 clinical trials for asthma.
|
30220562 |
2018 |
|
Asthma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Current treatment options for severe asthma are inadequate and therapeutic antibody-mediated depletion of CRTh2-expressing cells represents a promising new therapeutic strategy.
|
27103662 |
2016 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To ealuate the efficacy, safety, and pharmacokinetics of BI 671800, a CRTH2 antagonist, when added to inhaled corticosteroid therapy in adult patients with symptomatic asthma.
|
28234053 |
2017 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRTH2 antagonist monotherapy can safely improve lung function and quality of life, and reduce asthma exacerbations and SABA use in asthmatics.
|
30413187 |
2018 |